Profile data is unavailable for this security.
About the company
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
- Revenue in JPY (TTM)43.51bn
- Net income in JPY1.48bn
- Incorporated2002
- Employees1.84k
- LocationTakara Bio Inc7-4-38, Noji-HigashiKUSATSU-SHI 525-0058JapanJPN
- Phone+81 775656920
- Fax+81 775618007
- Websitehttps://www.takara-bio.co.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharma Foods International Co., Ltd. | 63.21bn | 3.87bn | 32.95bn | 670.00 | 8.38 | 3.18 | 7.33 | 0.5212 | 135.20 | 135.20 | 2,207.45 | 356.76 | 1.75 | 2.10 | 12.31 | 94,343,280.00 | 10.69 | 8.40 | 35.14 | 19.20 | 79.54 | 81.34 | 6.12 | 3.85 | 0.8573 | 93.61 | 0.6565 | 28.26 | 13.94 | 53.90 | 923.80 | 57.92 | 51.63 | -- |
| Chordia Therapeutics Inc | -100.00bn | -100.00bn | 44.17bn | 21.00 | -- | 11.12 | -- | -- | -- | -- | -- | 58.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 112.55 | -- | -- | -- |
| Shin Nippon Biomedical Laboratories Ltd | 26.45bn | 5.53bn | 51.54bn | 1.34k | 9.32 | 1.51 | 6.98 | 1.95 | 132.86 | 132.86 | 635.36 | 819.43 | 0.3961 | 1.24 | 5.08 | 19,724,440.00 | 8.26 | 10.54 | 12.43 | 15.93 | 54.00 | 52.73 | 20.86 | 25.32 | 0.7835 | -- | 0.4353 | 25.88 | 5.42 | 11.05 | -8.73 | 23.18 | 50.90 | 75.54 |
| SanBio Co Ltd | 0.00 | -2.16bn | 66.98bn | 29.00 | -- | 27.91 | -- | -- | -32.93 | -32.93 | 0.00 | 34.97 | 0.00 | -- | -- | 0.00 | -41.79 | -42.00 | -48.20 | -48.88 | -- | -- | -- | -4,790.72 | -- | -- | 0.1995 | -- | -- | -- | 52.44 | -- | 53.94 | -- |
| GNI Group Ltd | 27.75bn | 9.55bn | 120.67bn | 843.00 | 12.81 | 3.48 | 10.17 | 4.35 | 188.10 | 188.10 | 554.62 | 693.41 | 0.5569 | 2.01 | 7.89 | 32,921,710.00 | 22.45 | 7.23 | 26.73 | 8.80 | 84.78 | 85.75 | 40.32 | 14.57 | 2.74 | 30.59 | 0.1417 | 0.00 | 49.32 | 38.97 | 1,981.71 | -- | 19.69 | -- |
| Takara Bio Inc | 43.51bn | 1.48bn | 137.51bn | 1.84k | 92.91 | 1.23 | 21.39 | 3.16 | 12.29 | 12.29 | 361.29 | 926.00 | 0.3474 | 1.45 | 3.71 | 23,669,750.00 | 1.21 | 10.06 | 1.32 | 11.38 | 61.85 | 64.39 | 3.47 | 18.84 | 7.10 | -- | 0.0086 | 27.54 | -44.33 | 3.95 | -90.76 | -16.55 | 16.18 | 19.42 |
| Peptidream Inc | 27.97bn | 2.44bn | 355.71bn | 603.00 | 145.17 | 8.87 | 72.62 | 12.72 | 18.85 | 18.85 | 215.77 | 308.51 | 0.4323 | 4.20 | 5.14 | 46,391,190.00 | 3.77 | -- | 4.38 | -- | 59.16 | -- | 8.73 | -- | 3.23 | 2.59 | 0.3505 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 31 May 2024 | 1.91m | 1.58% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 1.58m | 1.31% |
| Nikko Asset Management Co., Ltd.as of 05 Jul 2024 | 838.10k | 0.70% |
| Daiwa Asset Management Co. Ltd.as of 28 Jun 2024 | 800.60k | 0.67% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 741.70k | 0.62% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 673.80k | 0.56% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 644.70k | 0.54% |
| Mellon Investments Corp.as of 03 Jul 2024 | 406.70k | 0.34% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jul 2024 | 405.70k | 0.34% |
| Kuwait Investment Authority (Investment Management)as of 31 Mar 2024 | 388.70k | 0.32% |
